Melanoma is the deadliest skin cancer, and its incidence has been increasing faster than any other cancer. Although immunogenic, melanoma is not effectively cleared by host immunity. In this study, we investigate the therapeutic, antimelanoma potential of the histone deacetylase inhibitor (HDACi) panobinostat (LBH589) by assessing both its cytotoxic effects on melanoma cells as well as enhancement of immune recognition of melanoma. Utilizing murine and human melanoma cell lines, we analyzed the effects of LBH589 on proliferation and survival. In addition, we analyzed the expression of several immunologically relevant surface markers and melanoma differentiation antigens, and the ability of LBH589-treated melanoma to activate antigen-specific T cells. Finally, we assessed the in-vivo effects of LBH589 in a mouse melanoma model. Low nanomolar concentrations of LBH589 inhibit the growth of all melanoma cell lines tested, but not normal melanocytes. This inhibition is characterized by increased apoptosis as well as a G1 cell cycle arrest. In addition, LBH589 augments the expression of major histocompatibility complex and costimulatory molecules on melanoma cells leading to an increased ability to activate antigen-specific T cells. Treatment also increases expression of melanoma differentiation antigens. In vivo, LBH589 treatment of melanoma-bearing mice results in a significant increase in survival. However, in immunodeficient mice, the therapeutic effect of LBH589 is lost. Taken together, LBH589 exerts a dual effect upon melanoma cells by affecting not only growth/survival but also by increasing melanoma immunogenicity. These effects provide the framework for future evaluation of this HDAC inhibitor in melanoma treatment.
Introduction
Skin cancers are the most common malignancies in the USA, and melanoma accounts for the majority of skin cancer-related mortality. Moreover, melanoma is one of the few cancers that has continued to increase in incidence over time and, therefore, so have deaths from this neoplasm [1] . Currently, metastatic melanoma has a 5-year survival of 15%, and few therapies exist which provide significant survival benefit [2] .
Overcoming tolerance mechanisms and directing the immune response towards a proinflammatory response represent major hurdles in developing effective immunotherapy strategies against cancer. An important factor determining T-cell activation, and the type of immune response, is the type and quality of effector cell interactions with antigen-presenting cells (APCs). Three signals between APCs and T cells direct the ensuing immune response. These are (a) presentation of antigen through major histocompatibility complex (MHC), (b) costimulatory molecules, and (c) cytokine signaling. Although classically associated with professional APCs, it has become increasingly evident that tumor cells harbor APC-like functions [3] [4] [5] . However, it is likely that this potential function is negatively affected by the immunosuppressive microenvironment that characterizes the tumor site, through the expression of inhibitory ligands such as PD-L1 and/or production of anti-inflammatory cytokines such as interleukin-10 (IL-10), vascular endothelial growth factor, or transforming growth factor-b [6, 7] . Strategies that are able to shift this microenvironment toward a proinflammatory phenotype may provide for more effective antitumor immunity.
HDAC inhibitors (HDACi) have demonstrated selective antiproliferative properties and cytotoxicity to tumor cells compared with minimal effects on normal cells [8] . Indeed, two HDACi have already been approved for the treatment of patients with refractory cutaneous T-cell lymphoma. However, their therapeutic efficacy in solid malignancies including melanoma remains to be fully explored. In addition to their direct cytotoxic effects, there is growing evidence supporting previously unknown immunoregulatory properties of HDACi. In the context of melanoma, studies have already demonstrated clear immunoregulatory effects of these compounds [9, 10] .
We sought to characterize the effects of the pan-HDACi LBH589 to assess its therapeutic potential for the treatment of melanoma, Herein we evaluated its direct antitumor effects in addition to its ability to modulate tumor immunogenicity. To this end, we found that LBH589 exerted direct cytotoxic effects on melanoma cells by the induction of apoptosis and G1 cell cycle arrest, and that it also enhanced the APC function of melanoma cells through upregulation of various immunerelevant receptors/ligands. This resulted in enhanced activation of antigen-specific T cells. In addition, LBH589 resulted in enhanced expression of melanoma antigens that have been previously described to be recognized by tumor infiltrating lymphocytes [11] . Importantly, these in-vitro effects translated into therapeutic benefit in vivo, with LBH589 treatment resulting in a significant increase in survival. Survival advantages were abrogated in immunodeficient mice, highlighting the importance of the immunoregulatory effects of LBH589 in the antitumor response.
Materials and methods
Mice C57BL/6 mice were purchased from NCI laboratories (Fredrick, Maryland, USA), and B6.129S7-Rag1 tm1Mom /J immunodeficient mice were purchased from Jackson laboratories (Bar Harbor, Massachusetts, USA). For invivo tumor studies, mice were injected subcutaneously into the shaved flank with 100 000 B16 melanoma cells suspended in Hank's Balanced Salt Solution (Invitrogen, Carlsbad, California, USA). All animal studies were performed in compliance with protocols approved by the IACUC at the University of South Florida.
Cells
Melanoma cell lines were obtained from the ATCC (Manassas, Virginia, USA) and cultured in RPMI 1640 supplemented with 10% fetal bovine serum, 100 IU/ml penicillin, and 100 mg/ml streptomycin. The human melanocyte cell line, HEMn-LP, was obtained from Invitrogen and grown in manufacturer suggested media, Medium 254 supplemented with HMGS. All cell lines were grown under humidified conditions at 371C and 5% CO 2 .
HDACi MGCD0103 was purchased from Selleck Chemicals (Houston, Texas, USA) and trichostatin A (TSA) from Sigma Aldrich (St Louis, Missouri, USA). LBH589 was kindly provided by Novartis (Basel, Switzerland). For invitro use, LBH589 was reconstituted in dimethyl sulfoxide (DMSO) at greater than 1000 Â the final effective dose. For in-vivo studies, LBH589 was dissolved in a 5% dextrose solution and sonicated to aide dissolution.
Determination of IC 50 by MTS
Cells were plated at 5 Â 10 3 /well in 96-well flat bottom plates. The following day, media was changed to that containing LBH589 or DMSO vehicle diluted in complete medium. Cells were incubated for 72 h. Density of viable, metabolically active cells was quantified using a standard MTS assay purchased from Promega (Fitchburg, Wisconsin, USA) as per manufacturer's instructions. Absorbance at 490 nmol/l was measured spectrophotometrically with background subtraction at 670 nmol/l. All values were then normalized and expressed as a percentage of DMSO control growth.
Flow cytometry
For surface marker analysis, melanoma cells were treated with LBH589 or DMSO for 48 h. Cells were stained with phycoerythrin, fluorescein isothiocyanate, or allophycocyanin-conjugated antibodies against MHC I, MHC II, CD40, CD80, or CD86. Conjugated antibodies were purchased from eBioscience (San Diego, California, USA). Cells were suspended in buffer containing DAPI (50 ng/ml) for viability.
For apoptosis analysis, melanoma cells were treated with LBH589 or DMSO for 48 h. Cells were then stained with Annexin V according to the manufacturer's (BD Biosciences, Franklin Lakes, New Jersey, USA) protocol. Cells were stained with fluorescein isothiocyanateconjugated Annexin V concomitantly with propidium iodide (PI) viability staining.
For cell cycle analysis, melanoma cells were treated with indicated doses of LBH589 or DMSO control for 48 h. Cells were washed and resuspended in 75% ethanol overnight. Samples were then washed and resuspended in PBS containing 0.1% Triton X-100. Finally, samples were treated with RNAse A and stained with PI.
A minimum of 10 000 events were collected for all experiments using an LSR II (BD Biosciences) or FACScan flow cytometer and subsequently analyzed using FlowJo software (Tree Star Inc., Ashland, Oregon, USA).
Quantitative reverse transcriptase PCR Cells were plated overnight then treated for 24 h with LBH589 or DMSO. Cells were then lysed using TRIzol from Invitrogen. RNA was isolated using a standard phenol-chloroform separation protocol, and cDNA was generated using IScript from Bio-Rad (Hercules, California, USA). Expression was assessed by quantitative reverse transcription-PCR using a SYBR Green system. Primers for human GAPDH (forward: GAAGGTCGG AGTCAACGGATT, reverse: ATGGGTGGAATCATATT GGAAC) and mouse 18s ribosomal RNA from Qiagen (Shanghai, China) were used for reference genes. Primers for human gp100 (forward: TGGAGAGGTGGTCAAGTG TC, reverse: TGGCAATACCTTTTGGCTTC), mart1 (forward: AAGGAAGGTGTCCTGTGCC, reverse: TCA GCCGTGGTGTAAGAGTG), tyrp1 (forward: GACATG CAGGAAATGTTGC, reverse: CATCAAGTCATCCGTG CAGA), and tyrp2 (forward: GCAAGTGCACAGGAAAC TTTG, reverse: CCGAATCACTGGTGGTTTCT) were utilized for human cells. Primers for mouse gp100 (forward: CATCAATGGGAGCCAGGTG, reverse: TTC GGAGGTTTAGGACCAGA), mart1 (forward: GGAAGG TGTCCTGTGCTGA, reverse: TGACATAGGAGCGTC TGTGC), tyrp1 (forward: GCAGCTCTGTGCTGTATT TTCA, reverse: GGGGGAGGACGTTGTAAGAT), and tyrp2 (forward: GTGCGACAGCTTGGATGACTA, reverse: CAGGCAATCTTGCACATTTTT) were utilized for murine cells.
T-cell activation studies
B16 melanoma cells were treated with indicated doses of LBH589 or DMSO for 48 h. Cells were then washed with media and subsequently ovalbumin (OVA)-specific antigen-specific CD4 + T cells (OT-II) plus OVA peptide (Ile-Ser-Gln-Ala-Val-His-Ala-Ala-His-Ala-Glu-Ile-Asn-GluAla-Gly-Arg) were added. Twenty-four hours later, supernatant was collected and assessed for cytokine production by a standard enzyme-linked immunosorbent assay protocol.
Statistical analysis
Significance of melanoma growth inhibition and T-cell cytokine production was determined by one-way analysis of variance using GraphPad Prism 5.0 software (GraphPad Software Inc., La Jolla, California, USA). In addition, GraphPad Prism 5.0 software was used to determine significance of survival curves. Values of P less than 0.05 were considered significant.
Results

HDAC inhibitors have direct antimelanoma activity in vitro
We initially determined the direct antimelanoma efficacy of various HDACi. As shown in Fig. 1a , the pan-HDAC inhibitors LBH589 and TSA in addition to the class 1-specific HDACi MGCD0103 inhibited the growth of murine melanoma B16 and two human melanoma lines, WM793 and WM983A. LBH589 had a potent effect on melanoma growth with IC 50 values in the low nanomolar range.
To further assess the antimelanoma activity of LBH589, its effects on additional human melanoma cell lines were assessed in vitro. All treated cell lines displayed significant, dose-dependent impairment in growth (Fig. 1b) . IC 50 values ranged from 25 to 100 nmol/l. Importantly, LBH589 inhibited the growth of human melanoma cells with different genotypic and phenotypic characteristics such as cell lines with BRAF mutations (WM793, WM983A, WM35, and WM164), melanoma cells with constitutively activated STAT3 (WM793), and the CDKN2A mutant cell line SKMEL21 [12] .
To determine the tumor selectivity of LBH589 upon cell growth inhibition we next assessed whether this compound impaired the growth of a nontransformed, human melanocyte cell line. As shown in Fig. 1b (open squares) at the concentrations used, no impairment in the growth of normal melanocytes was observed.
To mechanistically dissect the inhibitory effect of LBH589, we investigated two known effects of HDACi, cell death and cell cycle arrest [13, 14] . Measurement of viability and surface expression of phosphatidylserine evidenced a marked increase in cellular death in the three cell lines analyzed (Fig. 2a) . To investigate any potential cell cycle inhibitory effects of LBH589, PI staining of DNA in fixed cells 48 h after LBH589 treatment was used to determine cell cycle distribution. Consistent with previous reports of HDACi antitumor effects in other malignancies [15] , LBH589 induced a G1 cell cycle arrest in melanoma lines WM793 and WM983A (Fig. 2b) . In addition, a G2 arrest is apparent in WM983A, but not WM793 cells.
LBH589 augmented expression of immunologically relevant molecules in melanoma cells, enhancing T-cell activation
Previous reports have suggested an immunologic effect of HDACi on tumor cells. To address if such effects result from LBH589 treatment, we stained melanomas for various immunologically relevant molecules. In B16 cells, LBH589 treatment resulted in upregulation of MHC class I, MHC class II as well as the costimulatory molecules CD40, CD80, and modest upregulation of CD86 (Fig. 3a, row 1) . In WM793, LBH589 treatment resulted in similar upregulation of MHC class I and class II. However, although modest upregulation of CD40 and CD86 was noted, no differences in CD80 were seen (Fig. 3a, row 2) . As well, in WM983A upregulation of MHC class I was seen, but no changes in class II were observed. Increases in CD40 and CD86 expression were also seen, but no alterations were seen in CD80 levels (Fig. 3a, row 3) .
Next, we determined whether this enhanced expression of immunologically relevant molecules rendered melanoma + T cells encountering cognate peptide on LBH589-treated B16 cells produced significantly higher levels of both IL-2 and interferon g (IFN-g) as compared with T cells encountering antigen in untreated or DMSO-treated melanoma cells (Fig. 3b) .
Although enhanced expression of costimulatory molecules and MHC molecules can aid in directing the type and magnitude of the immune response, recognition of tumor by T cells is essential in generating an antitumor immune response. Consequently, we analyzed expression of several melanoma differentiation antigens in LBH589-treated melanoma. In both B16 and WM793 cells, expression of gp100, mart1, tyrp1, and tyrp2 was enhanced (Fig. 3c) .
The in-vivo antimelanoma efficacy of LBH589 requires an intact adaptive immune system Given these effects of LBH589 in vitro on melanoma cells, we assessed whether this would translate to a relevant antimelanoma effect in vivo. C57BL/6 mice were challenged with B16 melanoma cells injected subcutaneously. When tumors became palpable (> 3 mm), melanoma-bearing mice were randomly assigned to receive either 5% dextrose in PBS vehicle control, or LBH589 (25 mg/kg), each administered three times weekly by intraperitoneal injection. As shown in Fig. 4a , a significant increase in survival was observed in those mice treated with LBH589. 
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* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * To address the importance of enhancement of immunogenicity in generating a survival advantage, C57BL/6 SCID mice, lacking T and B cells, were also challenged with B16 melanoma cells. Unlike immunocompetent melanoma bearing, no survival advantage was observed in immunodeficient animals treated with LBH589. These results indicate that the antitumor effect of LBH589 required an intact adaptive immune system and points to the immunological antitumor effects triggered by LBH589 as playing a dominant role in its in-vivo antimelanoma activity.
Discussion
In the past several years, a number of therapeutic approaches have sought to improve the weak antigenpresenting capabilities of solid tumors by either genetically modifying these cells to enforce the expression of adhesion/ costimulatory molecules [16] or by using cytokines such as IFNs to upregulate the expression of MHC molecules in tumor cells in vivo [17] . Although these approaches generated productive immune responses, the duration and magnitude of these effects were transient and not strong enough to eradicate solid malignancies. Novel therapies endowed with the dual ability to influence tumor growth as well as its immunogenicity, such as shown here, might be more successful in triggering durable antitumor immune response against solid malignancies, including metastatic melanoma.
Previously our group demonstrated that the pan-HDACi LAQ824, which belongs to the same family of hydroxamic acid derivatives as LBH589, augmented the expression of MHC and costimulatory molecules in professional APCs by inhibiting the production of the immunosuppressive cytokine IL-10 and by increasing the production of several proinflammatory mediators. Such an effect resulted in the generation of inflammatory APCs that effectively activate antigen-specific CD4 + T cells and restore the responsiveness of anergic T cells [18] . As shown here, the positive immunological effects triggered by this family of HDAC inhibitors is not limited to professional APCs, as treatment of melanoma cells with LBH589 also resulted in increased immunogenicity and effective T-cell activation. However, it remains to be determined whether the changes observed in LBH589-treated melanoma cells involved the same mechanism(s) identified in professional APCs. Some evidence presented here point to some mechanistic differences. For instance, in APCs treated with LBH589 we have observed a consistent upregulation of MHC and B7.2 costimulatory molecules. This effect is however not always seen in human melanoma cells lines. It is possible that alternate epigenetic mechanisms are responsible for silencing CD86 in human melanoma cells, which might not be solely reverted by HDAC inhibition.
In this study, we have described a dual antimelanoma effect of the HDAC inhibitor LBH589: direct cytotoxicity and augmentation of melanoma immunogenicity. The direct cytotoxic effects of LBH589 are mediated by a G1 cell cycle arrest and induction of apoptosis in melanoma cells. Intriguingly, as seen in WM983A, LBH589 also is capable of inducing a G2 arrest in some melanomas. Although G2 arrests are less common in HDAC inhibitortreated cells than G1 arrests, such arrests are known to occur [19] . Melanoma cell lines are highly heterogeneous [20] , and it is likely that mutational differences in WM983A cells result in this G2 arrest. Future work is needed to test this hypothesis.
The immunological effects of LBH589 are largely due to augmentation of the APC function of melanoma cells through upregulation of immune-relevant receptors/ ligands leading to increased activation of antigen-specific T cells. In addition, robust increases in expression of melanoma differentiation antigens result from LBH589 treatment. Although enhancement of APC function by way of HDAC inhibitors has previously been reported [9] , few reports of this enhanced antigen expression exist [21] . The implications of this HDAC inhibitor-mediated antigen upregulation are potentially far reaching. For example, upregulation of melanoma antigens could be utilized to improve T-cell adoptive therapy by way of enhancing ex-vivo T-cell expansion or in-vivo tumor recognition. Further experiments will also need to address whether antigen upregulation is also seen in other malignancies and treatment with other HDAC inhibitors produces similar results.
Importantly, the demonstrated in-vitro properties of LBH589 treatment translate into positive in-vivo effects. LBH589 induces a significant increase in survival in melanoma-bearing mice. However, in mice lacking adaptive immunity this survival advantage is lost, highlighting the importance of the immunomodulatory effectors of LBH589.
Our demonstration that LBH589 is an effective therapeutic strategy in a murine model of melanoma provides the basis for evaluating the efficacy of this compound in human melanoma. The additional demonstration of aberrant expression of several HDACs in human melanoma cells [22, 23] provides further support for the evaluation of the therapeutic efficacy of LBH589 in this disease. Compared with LAQ824, for which clinical development was stopped, LBH589 has a better safety profile. An additional advantage of LBH589 is that it is an oral agent. These properties have led to the clinical LBH589 has potent antimelanoma properties Woods et al. 347 development of LBH589, which is currently undergoing evaluation in a phase III clinical trial for patients with multiple myeloma.
The previously unknown dual positive effects of LBH589 upon melanoma cells, together with our recent findings confirming that LBH589 is more potent than LAQ824 in inhibiting melanoma cell proliferation (data not shown), provide the framework for the future evaluation of LBH589 either as a single agent or in combination with other immunomodulatory agents such as ipilimumab in human metastatic melanoma.
